Search company, investor...

FIBREX Medical

Founded Year



Other Investors | Alive

About FIBREX Medical

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company is focused on pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. Per FIBREX, while inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

Headquarters Location

Gastgebgasse 5-13 Vienna


Missing: FIBREX Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: FIBREX Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing FIBREX Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

FIBREX Medical is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Digital Health

310 items

FIBREX Medical Patents

FIBREX Medical has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Peptides, Pharmacokinetics, Prodrugs, Drug discovery, Pharmaceutical industry


Application Date


Grant Date



Related Topics

Peptides, Pharmacokinetics, Prodrugs, Drug discovery, Pharmaceutical industry



Latest FIBREX Medical News

Atlas Venture’s Ankit Mahadevia Promoted to Principal

Mar 3, 2011

Atlas Venture’s Ankit Mahadevia Promoted to Principal March 3, 2011 By PEHub Administrator Ankit Mahadevia, who joined the Cambridge, Mass.-based venture firm Atlas Venture in 2008, has been promoted to principal, according to the firm. Mahadevia, who focuses on biotech and medtech for Atlas, currently sits on the boards of Lumavita, based in Basel, Switzerland, and Fibrex Medical, headquartered in Cambridge. Lumativa is developing drugs to combat infections, including the Herpes Simplex Virus and Human Papillomavirus infections of the cervix. Fibrex is a biopharmaceutical company focusing on cardiovascular and inflammatory diseases. Previously, Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, a specialty pharmaceutical company developing topical applications in neuropathic pain. Before Arcion Therapeutics, he held positions in Business Development at Genentech, and at Vanda Pharmaceuticals, a specialty pharmaceutical company focused on targeted therapies in psychiatry. He also served clients in the health services sector at McKinsey and Company. Mahadevia completed his MD at Johns Hopkins University School of Medicine, and his MBA at the Wharton School at the University of Pennsylvania. As an undergrad, he studied economics and biology at Northwestern University. © 2015 Buyouts Insider / Argosy Group LLC

FIBREX Medical Frequently Asked Questions (FAQ)

  • When was FIBREX Medical founded?

    FIBREX Medical was founded in 2001.

  • What is FIBREX Medical's latest funding round?

    FIBREX Medical's latest funding round is Other Investors.

  • Who are the investors of FIBREX Medical?

    Investors of FIBREX Medical include Atlas Venture.

  • Who are FIBREX Medical's competitors?

    Competitors of FIBREX Medical include Biolog, BioMarck Pharmaceuticals, REGiMMUNE, Maxygen, Merrimack Pharmaceuticals and 12 more.

Compare FIBREX Medical to Competitors


Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

ARC Pharmaceuticals Logo
ARC Pharmaceuticals

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Philogen Logo

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.